Form 4: Moderna CEO Stephane Bancel Receives Shares via Pro Rata Distribution

Moderna CEO Stephane Bancel received 26,840 shares of common stock through a pro rata distribution from Flagship Ventures Fund IV, while also reporting indirect ownership of shares held by Boston Biotech Ventures, LLC and OCHA LLC.

Summary

• On June 14, 2024, Stephane Bancel, CEO of Moderna, Inc., acquired 26,840 shares of Moderna's common stock.
• These shares were received as a pro rata distribution-in-kind from Flagship Ventures Fund IV, L.P., without any consideration paid by Bancel.
• Bancel also reported indirect beneficial ownership of 9,050,372 shares held by Boston Biotech Ventures, LLC, and 6,564,880 shares held by OCHA LLC.
• Bancel disclaims beneficial ownership of these indirectly held shares except to the extent of his pecuniary interest.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing, indicating a neutral sentiment. The pro rata distribution is a standard corporate action.

Positives

• The receipt of shares via pro rata distribution does not represent a direct purchase, indicating no change in Bancel's investment decision.

Industry Context

Reporting of beneficial ownership is standard practice for corporate insiders and is required by the SEC to ensure transparency in the market.

Comparison to Industry Standards

• Executive compensation often includes stock options and grants, but this transaction is a pro rata distribution, which is less common.
• Similar to other biotech executives, Bancel's ownership stake aligns his interests with those of shareholders.
• The reporting of indirect ownership through entities like Boston Biotech Ventures and OCHA LLC is consistent with SEC regulations regarding beneficial ownership.

Stakeholder Impact

• The transaction has a minimal direct impact on shareholders, as it is a distribution of existing shares rather than a new issuance.

Key Dates